Deborah Heart and Lung Center’s Chair of Electrophysiology, Raffaele Corbisiero, MD, and co-inventor David Muller of Abbott Laboratories, were awarded a patent for a novel way to optimally program CRT (cardiac resynchronization therapy) devices, based on a patients natural electrical conduction. The patent, which was issued on August 2, formalized a provisional patent issued two years ago. This new technique, tailored to each patient’s specific anatomy, ensures peak device performance.  Joining in congratulating Dr. Corbisiero (from left): S. Justin Szawlewicz, MD, Deborah Cardiology Chair; Janet Bennett, Deborah Vice President of Cardiology Services; and co-inventor David Muller.

Deborah Heart and Lung Center in Browns Mills, NJ is an 89-bed teaching hospital that specializes in the prevention, diagnosis, research, and treatment of heart, lung, and vascular diseases. Founded in 1922, Deborah has been a regional and nationally recognized leader throughout its 100-year history, during which time it has healed 2.3 million patients from every corner of the United States and 87 countries in the world. From performing the first open heart surgeries (adult and pediatric) in New Jersey, to running one of the highest volume left-ventricular assist device (LVAD) implant programs in the region, Deborah has stood at the forefront of medical innovation, all while never wavering from its founding mission “there is no price on life.” Deborah is consistently recognized as a leader in patient care from the Centers for Medicare and Medicaid Services, ranked among the top hospitals in New Jersey for patient satisfaction; holds a top-tier Society of Thoracic Surgeons rating which places Deborah among the best cardiac surgery programs in the country; and is designated a national Top Teaching Hospital by The Leapfrog Group. Deborah is an Alliance member of the Cleveland Clinic Heart, Vascular & Thoracic Institute.